Last updated: 2026-09-08 03:15:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BeyondSpring Inc. (BYSI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.61, with a market capitalisation of $25.42M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.57 to $2.44. This page covers its latest market performance, valuation, price trends and company information.
$25.42M | |
$0.63 | |
$48.49 | |
$0.54 | |
$0.62 | |
26.57K | |
677.00K | |
-- | |
$2.44 | |
$0.57 | |
-- | |
-- |
BeyondSpring Inc. (BYSI) last closed at $0.62 as of 2026-09-04 21:33:00, unchanged from the previous close of $0.62.
During the latest regular trading session, BYSI traded between $0.54 and $48.49, with a volume of 26.57K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, BeyondSpring Inc. (BYSI) moved from $0.64 to $0.61, representing a decline of 4.09% ($0.03).
The stock traded between $0.57 and $0.70 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 90.19 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2.6%
BYSI is currently trading at $0.61, placing it 2.6% of the way from its 52-week low of $0.57 to its 52-week high of $2.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 44 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BeyondSpring Inc. (BYSI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.